Nuo Therapeutics, Inc. (AURX) Return on equity 2017–2024
Nuo Therapeutics, Inc. (AURX) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-452.3%FY2024 · since FY2017: -3102.0% → -452.3%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2024 | -452.3% | -147.1 pp |
| FY2023 | -305.2% | -160.5 pp |
| FY2022 | -144.7% | -133.3 pp |
| FY2021 | -11.4% | — |
| FY2017 | -3102.0% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More AURX financial trends
AURX RevenueAURX Net incomeAURX Net marginAURX Gross profitAURX Gross marginAURX Operating incomeAURX Operating marginAURX Operating cash flowAURX Free cash flowAURX Capital expendituresAURX Stock buybacksAURX Dividends paidAURX Total assetsAURX Total liabilitiesAURX Shareholders’ equityAURX overview →